title: CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.
abstract: The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors.
authors.affiliation: Division of Solid Tumor Oncology, Departments of Medical Oncology and Urology, Sidney Kimmel Cancer Center at Thomas Jefferson University. wm.kevin.kelly@jefferson.edu.
authors.forename: Wm Kevin
authors.initials: WK
authors.lastname: Kelly
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Paul
authors.initials: P
authors.lastname: Marks
authors.affiliation: Discovery and Preclinical Sciences, Sanofi Oncology, Cambridge, Massachusetts.
authors.forename: Victoria M
authors.initials: VM
authors.lastname: Richon
mesh_terms: D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage*; D008297:Male
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids